Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
123M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
49.1M
-
Shares change
-
-1.9M
-
Total reported value, excl. options
-
$94.2M
-
Value change
-
-$22M
-
Number of buys
-
42
-
Number of sells
-
-44
-
Price
-
$1.92
Significant Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2018
112 filings reported holding CPRX - CATALYST PHARMACEUTICALS, INC. - COMMON STOCK as of Q4 2018.
CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.1M shares
of 123M outstanding shares and own 39.83% of the company stock.
Largest 10 shareholders include Consonance Capital Management LP (9.4M shares), BlackRock Inc. (6.97M shares), Broadfin Capital, LLC (6.27M shares), Vanguard Group Inc (4.83M shares), MORGAN STANLEY (3.25M shares), BAKER BROS. ADVISORS LP (2.9M shares), MANGROVE PARTNERS (2.37M shares), STATE STREET CORP (1.56M shares), ARMISTICE CAPITAL, LLC (1.38M shares), and NORTHERN TRUST CORP (1.13M shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.